Transactions in relation to share buyback program

Udgivet den 19-02-2019  |  kl. 09:37  |  

Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on market abuse and the delegated regulation (EU) no. 2016/1052 of 8 March 2016, also referred to as the Safe Harbor rules (company announcement no. 15 of May 2, 2018).

The share buyback program has been initiated in order to reduce the company's share capital and to cover obligations under the long-term incentive program. Under the share buyback program, which runs from May 2, 2018 and will end no later than March 14, 2019, GN intends to buy back shares for an amount of up to DKK 1,000 million.

The following transactions have been made under the program in the period February 12, 2019 - February 18, 2019:

  No. of shares Average purchase price, DKK Transaction Value, DKK
  February 12, 2019 24,060 299.31 7,201,307
  February 13, 2019 20,000 305.60 6,111,910
  February 14, 2019 20,552 305.77 6,284,152
  February 15, 2019 24,000 298.76 7,170,137
  February 18, 2019 14,700 298.58 4,389,123
Accumulated under the program 3,247,151 277.59 901,383,146

Following the above transactions GN holds a total of 13,984,192 own shares corresponding to a nominal value of DKK 55,936,768 and 9.6% of the total share capital and the total voting rights in the company. On a weekly basis, GN will announce the number and value of repurchased shares in company announcements to Nasdaq Copenhagen.

For further information, please contact:

Investors and analysts
Peter Justesen
VP - Investor Relations & Treasury
Tel: +45 45 75 87 16

Or

Rune Sandager
Senior Manager Investor Relations 
Tel: +45 45 75 92 57


Press and the media
Lars Otto Andersen-Lange
Head of Media Relations & Corporate Public Affairs
Tel: +45 45 75 02 55


About GN Group
The GN Group is a global leader in intelligent audio solutions that let you hear more, do more and be more than you ever thought possible. Our ambitious 150-year journey has taken us from telegraph cables to radio waves and intelligent audio engineering. To celebrate our anniversary, we look to our unique competences within medical, professional and consumer audio solutions to help us continue to transform lives through the power of sound. 

GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra and BlueParrott in 100 countries. Founded in 1869, the GN Group employs 6,000 people and is listed on Nasdaq Copenhagen (GN.CO).

Visit our homepage GN.com - and connect with us on LinkedIn, Facebook and Twitter.

Attachments

Announcement 8 - Transactions under share buyback program PUBLIC_sbb_GN_STORE_NORD

\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

17:49 Europa/lukning: Danske fedmeaktier blødte og trak Europa i rødt
17:19 Fredagens obligationer: Renter faldt efter amerikanske inflationstal
17:18 Novo banket i bund efter skuffende data - aktionærerne tabte omkring 690 mia. kr.
17:06 Fredagens aktier: Øretæver til Novo Nordisk og Zealand Pharma giver solid C25-nedtur
15:46 USA/åbning: Eli Lilly vinder på Novos kollaps mens inflationsdata skærer lidt af dykket
15:17 Jeudan har milliarder klar til opkøb: "Øget optimisme kan give flere transaktioner i 2025"
15:15 Novo/Jyske Bank: Kursreaktion virker som overreaktion
14:29 USA/tendens: Eli Lilly vinder på Novos kollaps mens frygt for nedlukning varsler rød start
13:33 Korr: Udsalg af Novo-aktier presser kronen
13:24 Udsalg af Novo-aktier presser kronen
12:29 Sydbank-analytiker: Voldsomt kursfald afspejler skuffelsen over Cagrisema-data
12:25 Europa/aktier: Danske fedmeaktier bløder og trækker Europa i rødt
12:22 Novo smadres på børsen efter skuffende fedmestudie - aktien taber 770 mia. kr.
12:11 Novos styrtdyk trækker C25-indekset ned i sit fjerdestørste fald nogensinde
12:09 Gubra og Zealand Pharma trækkes med ned af negativt nyt til Novo Nordisk
12:05 Novo lever ikke op til egne forventninger i vigtigt studie - aktien mister 900 mia kr -NY2
11:56 Novo lever ikke op til egne forventninger i kursfølsomt studie - aktien mister 700 mia kr
11:48 Aktier/middag: Zealand Pharma bankes tocifret ned efter FDA-afvisning og trækker C25 ned
11:28 Obligationer/middag: Små renteudsving før inflationsnyt fra USA
10:49 Jefferies ser kurslussing til Zealand Pharma som købsmulighed